Approval · Notice of Compliance 15658 · 2014
ACT SUMATRIPTAN: Notice of Compliance 15658
Issued May 28, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15658
- Date
- May 28, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- 5-ht1 receptor agonist; migraine therapy
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT SUMATRIPTAN | 02257882 | Cancelled Post Market |
| ACT SUMATRIPTAN | 02257890 | Cancelled Post Market |
| ACT SUMATRIPTAN | 02257904 | Cancelled Post Market |
Medicinal ingredients
- SUMATRIPTAN 25 MG per TAB
- SUMATRIPTAN 50 MG per TAB
- SUMATRIPTAN 100 MG per TAB